To this purpose, MNC isolated from bone marrow samples of CML patients at diagnosis were compared with MNC from bone marrow of CML patients who developed resistance to TK inhibitors for AURKA, PLK1 and FOXM1 expression levels and phosphorylation status. The gene discussed is AURKA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.